Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
14 March 2014
Answer given by Mr Borg on behalf of the Commission

The Commission intends to collect data on dementia from all EU Member States and the EEA/EFTA countries as from 2018 in the framework of the pilot morbidity data collection(1).

The Seventh Framework Programme for Research and Development (FP7, 2007-2013) dedicated EUR 555 million to research on dementia-related diseases. The Commission also supports the EU Joint Programming Initiative on Neurodegenerative Disease Research, in particular Alzheimer's(2), a Member States-led initiative coordinating efforts across countries. Since 2011, this initiative has committed EUR 75 million to joint actions.

Dementia research is also supported by the Innovative Medicines Initiative(3) (IMI), a public-private partnership between the EU and pharmaceutical industry. The IMI call of December 2013(4) includes the establishment of a ‘European Platform to Facilitate Proof of Concept for Prevention in Alzheimer’s Disease’ (EUR 53 Million). Neurodegenerative diseases, often associated with dementia, will also be a priority of the new Innovative Medicines Initiative 2 (IMI2)(5), whose proposed EU contribution is approximately EUR 1.6 billion. Horizon 2020, the new EU Programme for Research and Innovation (2014-2020)(6), will provide further opportunities for dementia research.

The results of the European Joint Action on dementia, Alzheimer Cooperative Valuation in Europe (ALCOVE), are published in a synthesis report(7). The Joint Action has produced recommendations on data collection, timely diagnosis, ethical and legal aspects, behavioural and psychological symptoms and limitations on the use of antipsychotic drugs. The outcomes of the project have been presented to the Member States. Follow-up activities are currently being considered.


OJ C 296, 03/09/2014
Last updated: 18 March 2014Legal notice